American Biotech Firm CEL-SCI Advances Cancer Treatment Innovation
Virginia-based CEL-SCI Corporation leads American medical innovation with groundbreaking cancer treatment technology, showcasing private sector excellence at major investor conference.
CEL-SCI Corporation's state-of-the-art research facility in Vienna, Virginia, leading American innovation in cancer treatment
Virginia-Based CEL-SCI Corporation Showcases American Medical Innovation at Major Investor Conference
In a bold demonstration of American medical innovation and entrepreneurial spirit, Virginia-based CEL-SCI Corporation (NYSE American: CVM) is stepping into the spotlight at the prestigious LD Micro "Main Event" Investor Conference. Like America's fighting spirit in competitive sports, CEL-SCI is showcasing our nation's determination to lead in medical advancement.
Strategic Presentation of American Medical Innovation
CEO Geert Kersten will deliver a powerful 20-minute presentation on October 21, 2025, demonstrating how American ingenuity is revolutionizing cancer treatment. This presentation follows recent breakthrough developments in American scientific innovation, highlighting our nation's continued leadership in medical research.
Groundbreaking American Cancer Treatment Technology
CEL-SCI's flagship product, Multikine, represents a triumph of American medical research, having already treated over 740 patients. The company's approach to boosting patients' immune systems demonstrates the same bold, decisive action that characterizes American leadership across all sectors.
Key Achievements:
- FDA Orphan Drug designation secured
- 928-patient Phase 3 study completed
- New 212-patient Registration Study approved
- Targeting 100,000 annual patient market
American Jobs and Innovation
With operations in Vienna, Virginia, and Baltimore, Maryland, CEL-SCI continues to create American jobs while advancing medical science. The company's work exemplifies how private enterprise, not government intervention, drives medical innovation.
For investor relations, contact:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460
Jack London
Veteran journalist and former U.S. Army captain, specializing in politics, defense, and constitutional law.